Articles On Actinogen Medical (ASX:ACW)

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

With the world focused on the outcome of clinical trials for a COVID-19 vaccine, new research may add a new layer of complexity to a trial process that mainly uses male animals and male humans in the development stages for drugs. A team of...

Dementia already affects hundreds of thousands of people in Australia, and it’s only going to get worse if a medical miracle is not forthcoming. The term relates to brain diseases, including Alzheimers, that impact a person’s ability to thi...

You may have heard the saying “it’s not brain surgery” in the context of trying to prove something easy. Well there is a reason  — our brains are among the most difficult parts of our body to treat. There are a few ASX small caps trying to...

Who said you have to be patient to net a hefty return on an investment? There are 10 ASX small caps that tripled (gained 200 per cent or more) in a day in 2019. Stockhead recaps the lucky companies and the reason for their show-stopping per...

There are no shortage of small cap health and biotech companies listed on the ASX — around 140 or so — but less than 25 are anywhere close to their ultimate dream of bringing a drug successfully to market, a Stockhead analysis has found. Ta...

The 10th Annual Australian Microcap Investment Conference will be held on Tuesday 22 October 2019 over two days at the Sofitel Melbourne on Collins. The Conference is Australia’s largest and most comprehensive emerging company investment ev...

Investors, brokers, high-ranking delegates, big pharma and Aussie small caps will all be sharing a room at the upcoming AusBiotech Invest & Partnering 2019 event in late October. The southern hemisphere’s biggest biotech investment even...

The Board of advanced Australian lithium developer Core Lithium (ASX: CXO) has announced the appointment of Malcolm McComas as a non-executive director, effective immediately. Mr McComas joins the Board as Core strengthens the organisation...

By Tim Boreham, Editor, The New Criterion When a stock is trading at a fraction of a cent, it’s usually a message for investors to abandon all hope and sell for the tax losses while they can. But ‘penny dreadful’ shares can sometimes rise...

In 2019, 10 stocks have gained more than 200 per cent in a single day. Stockhead recaps these stocks, why they gained and where they are now.   10. AssetOwl (ASX: AO1) +225% (16 April) A fellow micro-cap gave AssetOwl a massive leg up back...

Each Monday, Stockhead recaps which stocks are heavily demanded by investors — or running hot. Stockhead uses the Relative Strength Index (RSI), a technical gauge which measures how trading momentum is affecting the price action. A reading...

It wasn’t quite a case of ‘Lazarus with a triple bypass’, but a recovery of miraculous proportions did happen in the biotech sector last week as Actinogen (ASX:ACW) jagged some remarkable efficacy results from what otherwise a bog-standard...

ShareCafePicking The One Cent Wonders That Could Become Dollar Dazzlers When a stock is trading at a fraction of a cent, it’s usually a message for investors to abandon all hope and sell for the tax losses while they can. But ‘penny drea...

What's hot Immuron Limited (ASX:IMC) Immuron closed up 66% to finish at 17.5c on $3.69 million stock traded. The reason for the rise was a new research agreement with the Naval Medical Research Centre (NMRC), Silver Spring, MD, USA. AU$5.5...

On Stockhead today: are semiconductors about to pick up again, California’s first pot cafe opens, biotech losers’ remarkable comeback, and angel investment firm Investible closes with $22m round. But first:   The day ahead Today the Austral...

The three best-performing health and biotech companies in the past fortnight have all seen their shares fly on the back of positive clinical trial results — and the top two are companies trying to recover from previously disappointing trial...

The Australian benchmark index S&P/ASX200, last traded on 2 October 2019, at 6639.9 points, down by 1.5 percent from the prior close. Also, S&P/ASX200 Health Care (Sector) last traded on 2 October 2019 at 35,821.4 points, dipping do...

On Tuesday, Actinogen Medical (ASX:ACW) released extremely promising results from the XanaHES (Xanamem in Healthy Elderly Subjects) trial. Investors recognised the potentially company transforming nature of the results when they were releas...

On 1 October 2005, I was only 20 metres away from a large bomb that went off in the heart of Kuta. The 2005 Bali bombings were a series of terrorist attacks across two sites in Jimbaran Bay and in Kuta - 30km away from each other, both in s...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

On Stockhead today: Tim Treadgold on why gold miner Pantoro is a stock to watch, milk stocks in healthier shape thanks to Bellamy’s, Barry FitzGerald talks Salt Lake Pot Ash in Explorer’s Podcast and just how much do neobanks scare the Big...

The Actinogen Medical Ltd (ASX: ACW) share price is up 466% today from 0.9 cents to 5.1 cents after the biotech researcher reported positive clinical trial results for its Xanamem drug designed to treat cognitive impairment in the elderly....

Actinogen Medical (ASX: ACW) has announced “breakthrough” results from its XanaHES higher dose safety study first initiated last year. The results reaffirm the foundational hypothesis that reducing cortisol levels can improve cognition with...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

On Stockhead today: Aussie small caps trying to tackle the opioid crisis, which car manufacturers will survive the EV revolution, Barry FitzGerald looks at upcoming juniors, and how South Australian small caps are putting themselves back on...

On Stockhead today: our report on the 100 best performing stocks for the year, how four directors put in $5.1 million to make a quick $1.4 million, what are the hottest stocks on the ASX right now and Dr Boreham’s prognosis of Suda. But fir...

Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (easte...

Each Monday, Stockhead recaps which stocks are heavily demanded by investors – or running hot. Stockhead uses the Relative Strength Index (RSI), a measurement of comparative buying and selling momentum. A reading of 70 is seen as the level...